Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $265.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by Wells Fargo & Company from $250.00 to $265.00 in a report published on Wednesday,Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

A number of other analysts also recently weighed in on the stock. Raymond James Financial assumed coverage on shares of Jazz Pharmaceuticals in a report on Friday, April 10th. They issued an “outperform” rating and a $227.00 target price on the stock. TD Cowen restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Leerink Partners boosted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $230.56.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $225.79 on Wednesday. The company’s 50-day moving average price is $192.62 and its 200-day moving average price is $172.95. Jazz Pharmaceuticals has a twelve month low of $97.56 and a twelve month high of $230.40. The company has a quick ratio of 1.67, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a market cap of $14.17 billion, a PE ratio of -11,283.86, a price-to-earnings-growth ratio of 0.41 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The firm had revenue of $1.07 billion for the quarter. On average, equities research analysts forecast that Jazz Pharmaceuticals will post 20.51 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,287 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $182.94, for a total transaction of $235,443.78. Following the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 55,600 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the transaction, the executive vice president owned 56,862 shares in the company, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 74,015 shares of company stock worth $14,180,486 in the last three months. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in JAZZ. Royal Bank of Canada boosted its position in Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the period. Goldman Sachs Group Inc. boosted its position in Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after buying an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Jazz Pharmaceuticals by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares during the period. Focus Partners Wealth boosted its position in Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. boosted its position in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.